比阿培南对501株临床分离致病菌的体外抗菌活性研究

目的:评价比阿培南对501株临床分离致病菌的体外抗菌活性。方法:采用刃天青微孔板稀释法测定比阿培南和对照品(美罗培南、亚胺培南、头孢吡肟、头孢他啶、头孢哌酮/舒巴坦、环丙沙星、苯唑西林、万古霉素)对501株临床分离致病菌的体外抗菌活性。结果:比阿培南对大肠埃希菌、克雷伯菌属、产气肠杆菌、阴沟肠杆菌、志贺菌属、沙门菌属、变形杆菌属、沙雷菌属、柠檬酸菌属、不动杆菌属和铜绿假单胞菌的MIC50分别为0.06,0.13,0.25,0.13,0.03,0.03,1.00,0.50,0.13,0.13,0.50μg/mL;MIC90分别为0.13,0.13,0.50,0.50,0.03,0.06,1.00,0.50,0.25,0.25,4.00μg/mL。结论:比阿培南对临床分离致病菌的最低抑菌浓度MIC50、MIC90低于对照品。

Studies on Anti-microbe Actitivy in vitro of Biapenem Against 501 Strains of Bacteria Isolated

Objective： To evaluate antimierobe activity in vitro of biapcnem against 501 strains of bacteria isolated. Methods： Susceptibility of 501 swains of bacteria isolated to biapencm, meropcnem, imipcnem, cefepime, ciprofloxacin, cefopcrazone/sulbactam, ceflazidime, oxacillin and vancomycin were detected by microtitre plate-based antibacterial resazurin assay. Results： MICro of biapcnem against Escherickia, Klebsiella, Enterobacter, Shigella, Salmonella, Proteus, Serratia, Citrobacter and Pseudomonas aerugnosa are 0.125, 0.125, 0.50, 0.50, 0.03, 0.06, 0.25, 1.00, 0.50, 0.25 and 4.00 μg/mL, respectively; better than meropenem and imipenem. Conclusions： Minimum inhibitory concentrafion（MIC50, MIC90）of biapenem against 501 strains of bacteria isolated was lower than that of control antibiotics.